Due to missing patient identifiers, this case did not meet the criteria of a reportable adverse event at initial report. A 
medical doctor spontaneously reported via a Biogen Idec representative that a patient on TYSABRI (300 mg, IV, 
QM) for an unknown indication from unknown date to unknown date was hospitalized (dates of hospitalization not 
provided) for suspected PML (onset unknown). Testing included CSF JCV DNA (date unknown) which was 1400 
copies/ml. Treatment for the event was not provided. The event of suspected PML is ongoing. Causality for the 
event is unknown.  It is unknown if TYSABRI treatment is ongoing.
Update 01 Oct 2014: Due to a patient identifier received on follow-up, this case now meets the criteria of a 
reportable adverse event. The hospital neurologist spontaneously reported via a Biogen Idec Medical Science 
Liaison (MSL) that the male patient is doing well. The neurologist also reported that the patient has not yet 
experienced IRIS. No further information was provided.
Update 19 Mar 2015: Upon internal review, Biogen considers this case to be final call for high suspect PML based 
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 414 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
on lack of MRI details after multiple attempts to gather this additional data. This case will be closed and no 
additional follow-up is expected.